Ga-68 dotatate

NETSPOT links somatostatin analog dotatate to gallium-68, a positron-emitting isotope detectable by PET. It localizes receptor-positive neuroendocrine tumors and received US approval in 2016.

High-affinity binding to somatostatin receptor subtype 2 concentrates the tracer in receptor-rich, often well-differentiated tumor cells. Positrons create a PET signal showing lesions throughout the body, including small sites missed by other methods. In a prospective study it performed at least as well as, and often better than, older indium-111 receptor imaging and changed management in about one-third of patients. It does not itself treat tumors, though its receptor target is shared with therapeutic Lu-177 dotatate.

Supporting references: changed management.

FDA approved NETSPOT in 2016 for PET localization of somatostatin-receptor-positive neuroendocrine tumors in adults and children. A single IV injection precedes the scan. It helps locate/stage disease and select patients for receptor-targeted treatment. Long-acting somatostatin analog medicines can affect uptake, so their timing is considered by the imaging team.

Supporting references: approved.

Clinical studies identified no serious adverse reaction in the cited label account. Postmarketing reports include injection-site pain/burning, nausea and vomiting. Hypersensitivity is usually rash or itching but can include swelling or anaphylaxis-like reactions. As with other radiopharmaceuticals, radiation exposure is kept as low as reasonably achievable.